Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Abstract: The present invention relates to Chimeric Antigen Receptors (CARs) comprising antigen binding domains that specifically bind melanoma cells, polynucleotides encoding such CARs, and vectors comprising such polynucleotides. The present invention further relates to engineered cells comprising such polynucleotides and/or transduced with such viral vectors, and compositions including a plurality of engineered T cells. The present invention also relates to methods for manufacturing such engineered T cells and compositions and uses in treating a melanoma such engineered T cells and compositions.

Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Abstract: The invention provides methods and compositions for administration of allogeneic lymphocytes as an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.

Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.

Abstract: The present invention relates to the method for mass production of mesenchymal stem cell-derived proteins including various growth factors and cytokines, a mesenchymal stem cell conditioned medium containing a large amount of protein and produced by the above production method, cosmetic composition and pharmaceutical composition including the above conditioned medium for skin regeneration, anti-wrinkle, alopecia treatment, prevention of hair loss and promotion of hair growth.

Abstract: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux.

Abstract: Disclosed are methods for diagnosing Parkinson's disease, or identifying a risk of developing Parkinson's disease, comprising measuring the amount of a biomolecule in a blood sample, liver sample, or hepatocyte. Also disclosed are methods for preventing or treating Parkinson's disease, comprising administering a therapeutically effective plurality of hepatocytes to a subject in need thereof.

Abstract: Disclosed are methods, compositions of matter, and therapeutic protocols for treatment of cancer by selectively inducing immune responses against blood vessels feeding neoplastic tissue. In one embodiment, placental endothelial cells are stimulated with Phorbol Myristate Acetate (PMA) to induce release of nanoparticles that possess ability to: a) be taken up by antigen presenting; b) presented through direct and indirect presentation to CD4 and CD8 T cells, respectively; and c) utilized to stimulate cytoxic T cellular and humoral responses to selectively inhibit angiogenesis of tumors.

Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

Abstract: The present invention relates to a cell therapy product which is intended for regenerating a sphincter muscle and which contains stem cells derived from amniotic fluid, and more particularly, to a cell therapy product which is intended for regenerating the sphincter vesicae and which contains stem cells derived from amniotic fluid. Also, the cell therapy product of the present invention can be provided in the form of a formulation for administration through injection, said formulation being injected into a hydrogel complex to thereby improve the effects thereof. The composition including stem cells derived from amniotic fluid according to the present invention enables stem cells to be differentiated into muscles in the body of individual suffering from urinary incontinence by directly injecting the composition into the individual, thus effectively controlling urinary incontinence by recovering muscle functions.

Abstract: The present invention relates to placenta-derived cells excreting C3 or C1R complement proteins, a pharmaceutical composition containing same, and a method for treating diseases using the placenta-derived cells. The placenta-derived cells, according to the present invention, can be effectively applied to Alzheimer's disease, Parkinson's disease, HIV, neurodegenerative diseases such as dementia and epilepsy, or angiogenesis-related diseases such as cancer and retinopathy, thereby having high industrial utility.

Abstract: The present invention provides formulation/composition comprising phytonutrients with natural chlorotoxins for targeting cancer, infection, inflammation and pain without any side effects and a method for synthesizing the same. The raw materials are cleaned and dried and to prepare coarse powder of 40 mesh size, extracted with solvent (comprising water:alcohol in a ratio of 40:60) in a ratio of 4:1 with overnight soaking. Prior to cold extraction, the mixture is macerated for 4 hours. The mixture is refluxed for 2 hours at 80° C. The addition of ethanol, maceration and refluxing steps are repeated three times and above solvent is added, if required. The residue is checked for complete extraction after every refluxing step. The extract/residue is filtered and concentrated under vacuum. The extract/residue is vacuum tray dried at 70-80° C. for 12 hours. The extract/residue is scraped and dried lumps of the extract/residue are milled. The extract/residue is sieved and packed.

Abstract: The present invention provides formulation/composition comprising phytonutrients with natural chlorotoxins for targeting cancer, infection, inflammation and pain without any side effects and a method for synthesizing the same. The raw materials are cleaned and dried and to prepare coarse powder of 40 mesh size, extracted with solvent (comprising water: alcohol in a ratio of 40:60) in a ratio of 4:1 with overnight soaking. Prior to cold extraction, the mixture is macerated for 4 hours. The mixture is refluxed for 2 hours at 80° C. The addition of ethanol, maceration and refluxing steps are repeated three times and above solvent is added, if required. The residue is checked for complete extraction after every refluxing step. The extract/residue is filtered and concentrated under vacuum. The extract/residue is vacuum tray dried at 70-80° C. for 12 hours. The extract/residue is scraped and dried lumps of the extract/residue are milled. The extract/residue is sieved and packed.

Abstract: The present invention relates to compositions and methods for promoting the immune health of an animal or human by administering compositions or mixtures of water-soluble components derived from a genus Euglena organism that are capable of stimulating immune system activity in the absence of beta-glucan.

Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.

Abstract: The disclosure generally relates to microorganisms, methods, and compositions for reducing methionine content of a diet of a subject or extending a lifespan of the subject and processes for preparing the microorganisms and compositions.

Abstract: Prophylaxis or treatment of allergic airway inflammatory activity is described using Bifidobacterium longum NCIMB 41003. Also described is an exopolysaccharide which comprises the structure Formula (I). The polysaccharide may be used for treating or preventing undesirable inflammatory activity.

Abstract: The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.

Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.

Abstract: Provided are a composition for stimulating insulin secretion from cells, the composition including a Hypoxylon truncatum extract or an active ingredient thereof, and a method of stimulating insulin secretion from cells.

Abstract: The present invention relates to extracellular polysaccharide produced from Ceriporia lacerata, a mycelium culture medium of Ceriporia lacerata containing the extracellular polysaccharide, and a composition for preventing alopecia or stimulating hair growth containing dry powder or an extract of the mycelium culture medium as an active ingredient. The composition according to the present invention inhibits expression of TGF-? and is thus superb in preventing alopecia or stimulating hair growth and a composition containing said composition can be effectively used as a pharmaceutical composition, quasi-drug, healthy functional food and cosmetic composition for preventing alopecia or stimulating hair growth.

Abstract: An antibacterial essential oil includes 100 parts by weight of a Juniperus chinensis extract, 30 to 70 parts by weight of an Aquilaria agallocha extract, 30 to 70 parts by weight of camellia oil, and 10 to 40 parts by weight of a Dendropanax morbifera extract. Additionally, the antibacterial essential oil includes 10 to 40 parts by weight of a Portulaca oleracea extract, and 10 to 40 parts by weight of a Houttuynia cordata extract, 10 to 40 parts by weight of a Salicornia herbacea extract, and 10 to 40 parts by weight of a licorice extract. Further, the antibacterial essential oil includes 10 to 40 parts by weight of an Arctium lappa tea extract, 10 to 40 parts by weight of a jujube extract, 10 to 40 parts by weight of a Paeonia japonica extract, and 10 to 40 parts by weight of a Chamaecyparis obtuse extract.

Abstract: Methods for the production of different cannabis product compositions. Method for the production of at least two different cannabis product compositions from a solid cannabis plant material are described including providing a solid cannabis plant material containing at least one cannabinoid and at least one terpene at cannabinoid to terpene weight/weight ratio R100; first extracting from said solid cannabis plant material a first composition comprising at least 10% but less than 90% of said cannabinoid and at least 1% of said terpene at cannabinoid to terpene weight/weight ratio R101, wherein R101 differs from R100 by at least 10%; second extracting from said solid cannabis plant material a second composition comprising at least 10% of said cannabinoid and at least 1% of said terpene at cannabinoid to terpene weight/weight ratio R102, wherein R102 differs from R101 by at least 10%; and optionally refining said first composition, said second composition, or both.

Abstract: Embodiments of the invention are directed to compositions, kits and methods for minimizing unsightly post-procedural effects associated with an oculoplastic procedure. The composition can include escin, arnica and phytonadione in a pharmacologically acceptable carrier.

Abstract: Methods of tissue culture and in vitro propagation of medicinal plants, in particular, plants of the genera Hydrastis, Echinacea, Kalanhoe, Thymus and Calendula are described. Methods of genetically engineering the medicinal plants are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants to subjects in need thereof are provided.

Abstract: The invention provides compositions and methods for treating neurological disorders and viral infection using whole-grain flaxseed, flaxseed lignans such as Secoisolariciresinol diglucoside (SDG), human lignans metabolized from flaxseed such as Enterodiol (ED) or Enterolactone (EL), and synthetic flaxseed lignan analogs.

Abstract: The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption.

Abstract: Analgesic compositions and methods comprise various ingredients in synergistic quantities, and most preferably a turmeric component, a ginger component, a Burseraceae component, a skullcap component, and a collagen component in synergistic ratios that provide substantial analgesic effects when administered to a human. Especially preferred compositions comprise individual components at quantities below those commonly used for the individual component to produce an analgesic effect. It is contemplated that the compositions produce analgesic effects comparable to NSAIDs without adverse side effects observed with NSAID formulations.

Abstract: The present invention relates to an aqueous composition comprising apomorphine or a pharmaceutically acceptable salt or solvate thereof, reduced glutathione (GSH) or a pharmaceutically acceptable salt thereof, and ascorbic acid or a pharmaceutically acceptable salt or derivative thereof, wherein the composition has a pH of about 3 to about 7.4. The aqueous composition according to the invention exhibits superior tolerability and an improved side effect profile, particularly a reduced occurrence of skin nodule formation and panniculitis, when administered subcutaneously. The invention further relates to the composition for use as a medicament, particularly for the treatment of Parkinson's disease.

Abstract: The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.

Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).

Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.

Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.

Abstract: The present invention provides methods and compositions for diagnosing and treating intellectual disability (ID). The invention also provides methods and compositions for developing and using in-vitro and in vivo models for diagnosis and treatment as well as testing.

Abstract: Methods for treating learning disabilities associated with fetal alcohol syndrome and other neurological disorders by administering SK channel blockers, antagonists, inhibitors or modifiers like tamapin.

Abstract: The present invention provides formulation/composition comprising phytonutrients with natural chlorotoxins for targeting cancer, infection, inflammation and pain without any side effects and a method for synthesizing the same. The raw materials are cleaned and dried and to prepare coarse powder of 40 mesh size, extracted with solvent (comprising water: alcohol in a ratio of 40:60) in a ratio of 4:1 with overnight soaking. Prior to cold extraction, the mixture is macerated for 4 hours. The mixture is refluxed for 2 hours at 80° C. The addition of ethanol, maceration and refluxing steps are repeated three times and above solvent is added, if required. The residue is checked for complete extraction after every refluxing step. The extract/residue is filtered and concentrated under vacuum. The extract/residue is vacuum tray dried at 70-80° C. for 12 hours. The extract/residue is scraped and dried lumps of the extract/residue are milled. Additional natural product powders are added to the milled powder.

Abstract: The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.

Abstract: The present invention provides methods for treating hair loss, treating, inhibiting, or suppressing a degenerative skin disorder, treating androgenetic alopecia (AGA), generating new hair follicles (HF), and increasing the size of existing HF. The methods comprise epidermal disruption or administration of wnt, and administration of a fibroblast growth factor-9 polypeptide or another compound that upregulates sonic hedgehog gene signaling.

Abstract: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.

Abstract: The present invention relates to a stabilized external preparation comprising thymosin beta 4 (T?4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of T?4. The preparation according to the present invention provides T?4 in a stable state by maintaining the biological activity of T?4 and minimizing the generation of T?4 sulfoxide through oxidization reactions and multimers through aggregation.

Abstract: The present invention relates to compositions and peptides having agonist activity towards both the human GLP-1 receptor and the human GLP-2 receptor, wherein the relative agonist activity of the dual peptide towards the human GLP-1 receptor (GLP-1Rrelative) is at least 0.01, and wherein the relative agonist activity of the dual peptide towards the human GLP-2 receptor (GLP-2rrelative) is at least 0.01, and wherein (GLP-1Rrelative)(GLP-2Rrelative) is at least 0.01, as well as methods of production and uses thereof. Further, the invention relates to lipidated analogs of the peptides. The invention further relates to the treatment or prophylactic treatment of human diseases, in particular gut and brain relates diseases or metabolic disorders, such as gastrointestinal inflammation, short bowel syndrome and Crohn's disease.

Abstract: The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide drugs with advantageously high bioavailability, safety and costeffectiveness. In particular, the invention provides a peptide drug having a molecular weight of equal to or less than 5 kDa for use as a medicament, wherein said peptide drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex, and with a pharmaceutically acceptable complexing agent. The invention also provides a pharmaceutical composition comprising: a peptide drug having a molecular weight of equal to or less than 5 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex; and a pharmaceutically acceptable complexing agent.

Abstract: A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject.

Abstract: An agent for protecting upper respiratory tracts or a food or drink composition for protecting upper respiratory tracts which is effective in ameliorating various symptoms relating to upper respiratory tracts is provided. An agent for protecting upper respiratory tracts and a food or drink composition for protecting upper respiratory tracts containing lactoferrin, lactoperoxidase, glucose oxidase, glucose source, and a pH adjusting component as active ingredients is provided. The agent for protecting an upper respiratory tract according to the present invention and the food or drink composition for protecting an upper respiratory tract can ameliorate various symptoms relating to upper respiratory tracts.

Abstract: An effective amount of botulinum toxin type B is administered to a subject in need thereof for treating Raynaud's phenomenon. Botulinum toxin type B may be in a form of an injection, and may be locally administered to a disease affected site, in a dose of 200 to 400 units per disease affected site.

Abstract: The invention pertains to novel compositions and related method for stimulating the immune system to promote the apoptosis of malignant cells while inhibiting the apoptosis of normal cells by employing compositions of thioretinamide with organic allyl sulfides or furanonaphthoquinones and in particular diallyl trisulfide, napabucasin and optionally with pancreatin and/or cobalamin. The novel compositions and method are designed to work with the immune system to treat a wide variety of malignant neoplasms which involve working with an immune system or a reduced functioning of the immune system.